Viatris (VTRS) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026

Viatris · Health Care · ref. ETF XLV · 50 calls · price $17.25

🏆JPI 2026 portfoliosSee tracking →

What the company does: Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East.

📈 Viatris (VTRS) stock price

$17.25+73.7% over range

Oct 14, 25low $9.93 · high $18.27Oct 13, 26

📏 Click 2 points (left → right) to measure the change · click again to clear.

SellBuy

Buy

75% recommend buying · 8 analysts

📊 JPI status : Viatris has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 VTRS price target & analyst consensus — price $17.25

The price target · all analysts combined (8 targets)

Highest target · 1 firm of 8$26+50.7%

Median target · of 8 targets$20+15.9%

Lowest target · 1 firm of 8$13-24.6%

Current price$17.25

Where these 8 targets sit · versus the current price · 1 target per firm, last 6 months

Above the price 788% $18 ↔ $26

Below 113% $13

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 66% of its targets hit on this sector (358 calls tested). It aims for $26 (+51 %), call made on October 6, 2026, maturing on October 6, 2027 (8 d ago).

The 5 reliable analysts $20+16 %

The 3 other firms $20+16 %

How to read it: the 5 reliable firms are not filtered by optimism — 4 aim above the price, 1 below, hence their $20 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

The consensus · 8 ratings (last 6 months)

Strong Buy00%

Buy675%

Hold225%

Sell00%

Strong Sell00%

Go deeper on the analysts

🎯 VTRS price target all

All 50 calls, one by one, with our verdict on each firm.

→ See all 50 targets, analyst by analyst

💡 The best analysts on VTRS most reliable

The case for and against, with the numbers, per those who've been right on the stock.

→ Should you invest in VTRS? The case for & against

All analysts (the consensus) · vs · the best (those who've been right)

💬 A question about Viatris? The JPI assistant answers using our backtest data.

💰 Viatris dividend: yield, history & growth › open the full page

2.97%annual yield

That's ~$0.48 per share per year.

📈 Viatris fundamentals: valuation, margins & growth › open the full page

P/E —Net margin -2.8 %Revenue growth +4.9 %Not (yet) profitable

Revenue, net income and margin per year

Revenue Net income · hover a bar for details

2022

marg. 13 %

2023

Rev −5%Profit −97%

2024

Rev −4%Profit −1259%

2025

Rev −3%

🔎 Detailed analyses

📊 Returns & performance 💰 Dividend 📈 Fundamentals 💡 Why invest: the case for & against

🏛️ Which US Congress members hold Viatris (VTRS)?

6 Congress members have disclosed VTRS buys. Click a highlighted name to see their track record (do they beat the S&P 500?).

Josh Gottheimer 1× · 56%Kathy Manning 1× · 43%Earl Blumenauer 1× · 38%Daniel Goldman 1× · 25%Rob Bresnahan 1× · 31%Gilbert Cisneros 1× · 48%

→ Full members ranking (who beats the market)

✅ Historical analyst reliability on VTRS

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕	% right i ↕	Gain vs sector i ↕	Calls i ↕
Jefferies ↗	50%	+24.8%	2
Barclays ↗	33%	-9.5%	6
Raymond James ↗	0%	-10.4%	2
B of A Securities ↗	0%	-50.5%	2

📊 What $1,000 invested in Viatris would be worth › open the full page

In short — $1,000 invested in Viatris 10 years ago would be worth $352 today, i.e. -10%/yr on average. Best year: 2025 (+62%), worst: 2019 (-35%). Price performance, excluding dividends.

If I'd invested $1,000 in Viatris

Investment	Worth today	Gain
1 years ago	$1,720	+72%
3 years ago	$1,393	+39%
5 years ago	$1,069	+7%

→ See Viatris's full return history + gain calculator

Return by year (Viatris)

Year	Return	$1,000 invested at year start
2026 (YTD)	+6%	$1,064 (+6%)
2025	+62%	$1,720 (+72%)
2024	-25%	$1,284 (+28%)

→ See Viatris's full return history + gain calculator

⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Viatris

Loading news…

📋 All analyst calls on VTRS

UBS ↗

Oct 5, 26

▲ Buy · 🎯$26

Price at call : $17.54 — upside +48%

Today : $17.25 — upside +51%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 51.7% · +3.1% (358 calls)

in progress (365j)
matures : Oct 5, 27

Oppenheimer ↗

Sep 23, 26

▲ Outperform · 🎯$25

Price at call : $17.12 — upside +46%

Today : $17.25 — upside +45%

🎯 on VTRS : no call matured yet · 📊 on Health : 43.5% · -0.2% (223 calls)

in progress (365j)
matures : Sep 23, 27

Piper Sandler ↗

Sep 16, 26

■ Neutral neutral · not a buy · 🎯$13

Price at call : $17.13 — gap to target -24%

Today : $17.25 — gap to target -25%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Sep 16, 27

Leerink Partners ↗

Sep 9, 26

▲ Outperform · 🎯$20

Price at call : $16.38 — upside +22%

Today : $17.25 — upside +16%

🎯 on VTRS : no call matured yet · 📊 on Health : 53.7% · -6.2% (41 calls)

in progress (365j)
matures : Sep 9, 27

Argus Research ↗

Sep 8, 26

▲ Buy · 🎯$20

Price at call : $16.61 — upside +20%

Today : $17.25 — upside +16%

🎯 on VTRS : no call matured yet · 📊 on Health : 55.3% · +2.1% (159 calls)

in progress (365j)
matures : Sep 8, 27

Barclays ↗

May 19, 26

▲ Overweight · 🎯$22

Price at call : $16.17 — upside +36%

Today : $17.25 — upside +28%

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

in progress (365j)
matures : May 19, 27

JP Morgan ↗

May 8, 26

■ Neutral neutral · not a buy · 🎯$18

Price at call : $16.92 — gap to target +6%

Today : $17.25 — gap to target +4%

🎯 on VTRS : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)

in progress (365j)
matures : May 8, 27

Truist Securities ↗

May 8, 26

▲ Buy · 🎯$20

Price at call : $16.92 — upside +18%

Today : $17.25 — upside +16%

🎯 on VTRS : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)

in progress (365j)
matures : May 8, 27

See the other 42 calls, newest to oldest

Barclays ↗

Mar 24, 26

▲ Overweight · 🎯$17

Price at call : $13.5 — upside +26%

Today : $17.25 — upside -1%

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

in progress (365j)
matures : Mar 24, 27

Piper Sandler ↗

Jan 28, 26

■ Neutral neutral · not a buy · 🎯$12

Price at call : $12.97 — gap to target -7%

Today : $17.25 — gap to target -30%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Jan 28, 27

Argus Research ↗

Jan 16, 26

▲ Buy · 🎯$15

Price at call : $12.86 — upside +17%

Today : $17.25 — upside -13%

🎯 on VTRS : no call matured yet · 📊 on Health : 55.3% · +2.1% (159 calls)

in progress (365j)
matures : Jan 16, 27

Barclays ↗

Dec 9, 25

▲ Overweight · 🎯$15

Price at call : $11.6 — upside +29%

Today : $17.25 — upside -13%

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

in progress (365j)
matures : Dec 9, 26

Truist Securities ↗

Oct 15, 25

▲ Buy · 🎯$15

Price at call : $9.98 — upside +50%

Today : $17.25 — upside -13%

🎯 on VTRS : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)

in progress (365j)
matures : Oct 15, 26

Goldman Sachs ↗

Jun 6, 25

■ Neutral neutral · not a buy · 🎯$10

Price at call : $8.81 — gap to target +14%

Today : $17.25 — gap to target -42%

🎯 on VTRS : no call matured yet · 📊 on Health : 51.4% · +2.3% (243 calls)

in progress (365j)
matures : Jun 6, 26

Jefferies ↗

Mar 7, 25

▲ Buy · 🎯$13

Price at call : $9.5 — upside +37%

Today : $17.25 — upside -25%

Expected +37% · Actual +50% · Reason (≥ +15%) : ✓ Yes

🎯 on VTRS : 50% (2 calls matureds) · 📊 on Health : 51.2% · +4.7% (383 calls)

+49.7%

stock +50% · XLV +4%

matured Mar 7, 26

Piper Sandler ↗

Mar 5, 25

■ Neutral neutral · not a buy · 🎯$10

Price at call : $9.51 — gap to target +5%

Today : $17.25 — gap to target -42%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Mar 5, 26

Barclays ↗

Feb 28, 25

▼ Underweight · 🎯$9

Price at call : $9.33 — upside -4%

Today : $17.25 — upside -48%

Expected -4% · Actual +68% · Reason (≤ −15%) : ✗ No

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

-68.3%

stock +68% · XLV +6%

matured Feb 28, 26

B of A Securities ↗

Feb 28, 25

▼ Underperform · 🎯$10

Price at call : $9.23 — upside +8%

Today : $17.25 — upside -42%

Expected +8% · Actual +70% · Reason (≤ −15%) : ✗ No

🎯 on VTRS : 0% (2 calls matureds) · 📊 on Health : 48.1% · +2.0% (362 calls)

-70.1%

stock +70% · XLV +6%

matured Feb 28, 26

Piper Sandler ↗

Dec 6, 24

■ Neutral neutral · not a buy · 🎯$14

Price at call : $12.72 — gap to target +10%

Today : $17.25 — gap to target -19%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Dec 6, 25

Barclays ↗

Nov 8, 24

▼ Underweight · 🎯$12

Price at call : $13.09 — upside -8%

Today : $17.25 — upside -30%

Expected -8% · Actual -22% · Reason (≤ −15%) : ✓ Yes

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

+22.3%

stock -22% · XLV -1%

matured Nov 8, 25

Piper Sandler ↗

Mar 28, 24

■ Neutral neutral · not a buy · 🎯$13

Price at call : $11.94 — gap to target +9%

Today : $17.25 — gap to target -25%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Mar 28, 25

Piper Sandler ↗

Nov 22, 23

■ Neutral neutral · not a buy · 🎯$11

Price at call : $9.43 — gap to target +17%

Today : $17.25 — gap to target -36%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Nov 21, 24

B of A Securities ↗

Oct 23, 23

▼ Underperform · 🎯$9

Price at call : $8.92 — upside +1%

Today : $17.25 — upside -48%

Expected +1% · Actual +31% · Reason (≤ −15%) : ✗ No

🎯 on VTRS : 0% (2 calls matureds) · 📊 on Health : 48.1% · +2.0% (362 calls)

-30.8%

stock +31% · XLV +19%

matured Oct 22, 24

Barclays ↗

Jun 23, 23

▼ Underweight · 🎯$11

Price at call : $9.76 — upside +13%

Today : $17.25 — upside -36%

Expected +13% · Actual +7% · Reason (≤ −15%) : ✗ No

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

-7.3%

stock +7% · XLV +11%

matured Jun 22, 24

Barclays ↗

Apr 25, 23

■ Equal-Weight neutral · not a buy · 🎯$11

Price at call : $9.18 — gap to target +20%

Today : $17.25 — gap to target -36%

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

in progress (365j)
matures : Apr 24, 24

Barclays ↗

Apr 24, 23

■ Equal-Weight neutral · not a buy · 🎯$11

Price at call : $9.33 — gap to target +18%

Today : $17.25 — gap to target -36%

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

in progress (365j)
matures : Apr 23, 24

Barclays ↗

Feb 28, 23

▲ Overweight · 🎯$16

Price at call : $11.4 — upside +40%

Today : $17.25 — upside -7%

Expected +40% · Actual +8% · Reason (≥ +15%) : ✗ No

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

+7.8%

stock +8% · XLV +15%

matured Feb 28, 24

BMO Capital ↗

Feb 17, 23

■ Market Perform neutral · not a buy · 🎯$14

Price at call : $11.69 — gap to target +20%

Today : $17.25 — gap to target -19%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 60.4% · +8.8% (240 calls)

in progress (365j)
matures : Feb 17, 24

Barclays ↗

Feb 1, 23

▲ Overweight · 🎯$15

Price at call : $12.26 — upside +22%

Today : $17.25 — upside -13%

Expected +22% · Actual -3% · Reason (≥ +15%) : ✗ No

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

-3.2%

stock -3% · XLV +6%

matured Feb 1, 24

Jefferies ↗

Jan 27, 23

▲ Buy · 🎯$15

Price at call : $11.89 — upside +26%

Today : $17.25 — upside -13%

Expected +26% · Actual -0% · Reason (≥ +15%) : ✗ No

🎯 on VTRS : 50% (2 calls matureds) · 📊 on Health : 51.2% · +4.7% (383 calls)

-0.1%

stock -0% · XLV +6%

matured Jan 27, 24

JP Morgan ↗

Nov 15, 22

■ Neutral neutral · not a buy · 🎯$14

Price at call : $11.08 — gap to target +26%

Today : $17.25 — gap to target -19%

🎯 on VTRS : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)

in progress (365j)
matures : Nov 15, 23

UBS ↗

Nov 10, 22

■ Neutral neutral · not a buy · 🎯$12

Price at call : $11.34 — gap to target +6%

Today : $17.25 — gap to target -30%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 51.7% · +3.1% (358 calls)

in progress (365j)
matures : Nov 10, 23

Piper Sandler ↗

Nov 8, 22

■ Neutral neutral · not a buy · 🎯$10

Price at call : $11.1 — gap to target -10%

Today : $17.25 — gap to target -42%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Nov 8, 23

Barclays ↗

Oct 25, 22

▲ Overweight · 🎯$16

Price at call : $9.78 — upside +64%

Today : $17.25 — upside -7%

Expected +64% · Actual -8% · Reason (≥ +15%) : ✗ No

🎯 on VTRS : 33% (6 calls matureds) · 📊 on Health : 50.1% · +2.0% (645 calls)

-8.3%

stock -8% · XLV -3%

matured Oct 25, 23

Jefferies ↗

Oct 21, 22

■ Hold neutral · not a buy · 🎯$11

Price at call : $9.38 — gap to target +17%

Today : $17.25 — gap to target -36%

🎯 on VTRS : 50% (2 calls matureds) · 📊 on Health : 51.2% · +4.7% (383 calls)

in progress (365j)
matures : Oct 21, 23

BMO Capital ↗

Aug 9, 22

▲ Outperform · 🎯$16

Price at call : $10.46 — upside +53%

Today : $17.25 — upside -7%

Expected +53% · Actual +8% · Reason (≥ +15%) : ✗ No

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 60.4% · +8.8% (240 calls)

+7.6%

stock +8% · XLV +3%

matured Aug 9, 23

UBS ↗

Jun 14, 22

▼ Sell · 🎯$9

Price at call : $10.7 — upside -16%

Today : $17.25 — upside -48%

Expected -16% · Actual -7% · Reason (≤ −15%) : ✗ No

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 51.7% · +3.1% (358 calls)

+7.1%

stock -7% · XLV +9%

matured Jun 14, 23

Goldman Sachs ↗

May 12, 22

■ Neutral neutral · not a buy · 🎯$11

Price at call : $11.08 — gap to target -1%

Today : $17.25 — gap to target -36%

🎯 on VTRS : no call matured yet · 📊 on Health : 51.4% · +2.3% (243 calls)

in progress (365j)
matures : May 12, 23

Piper Sandler ↗

May 10, 22

▼ Underweight · 🎯$10

Price at call : $10.46 — upside -4%

Today : $17.25 — upside -42%

Expected -4% · Actual -8% · Reason (≤ −15%) : ✗ No

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

+8.3%

stock -8% · XLV +5%

matured May 10, 23

Piper Sandler ↗

Mar 16, 22

■ Neutral neutral · not a buy · 🎯$10

Price at call : $10.64 — gap to target -6%

Today : $17.25 — gap to target -42%

🎯 on VTRS : 100% (1 call matured) · 📊 on Health : 46.6% · -1.4% (324 calls)

in progress (365j)
matures : Mar 16, 23

Citigroup ↗

Mar 10, 22

■ Neutral neutral · not a buy · 🎯$11

Price at call : $10.12 — gap to target +9%

Today : $17.25 — gap to target -36%

🎯 on VTRS : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)

in progress (365j)
matures : Mar 10, 23

B of A Securities ↗

Mar 1, 22

■ Neutral neutral · not a buy · 🎯$13

Price at call : $10.15 — gap to target +28%

Today : $17.25 — gap to target -25%

🎯 on VTRS : 0% (2 calls matureds) · 📊 on Health : 48.1% · +2.0% (362 calls)

in progress (365j)
matures : Mar 1, 23

Raymond James ↗

Mar 1, 22

■ Market Perform neutral · not a buy

🎯 on VTRS : 0% (2 calls matureds) · 📊 on Health : 46.4% · +1.6% (403 calls)

in progress (365j)
matures : Mar 1, 23

Citigroup ↗

Jun 15, 21

■ Neutral neutral · not a buy · 🎯$16

Price at call : $15.3 — gap to target +5%

Today : $17.25 — gap to target -7%

🎯 on VTRS : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)

in progress (365j)
matures : Jun 15, 22

Morgan Stanley ↗

Mar 10, 21

■ Equal-Weight neutral · not a buy · 🎯$16

Price at call : $14.1 — gap to target +13%

Today : $17.25 — gap to target -7%

🎯 on VTRS : no call matured yet · 📊 on Health : 51.6% · +5.2% (830 calls)

in progress (365j)
matures : Mar 10, 22

Goldman Sachs ↗

Mar 8, 21

■ Neutral neutral · not a buy · 🎯$15

Price at call : $13.83 — gap to target +8%

Today : $17.25 — gap to target -13%

🎯 on VTRS : no call matured yet · 📊 on Health : 51.4% · +2.3% (243 calls)

in progress (365j)
matures : Mar 8, 22

JP Morgan ↗

Mar 2, 21

■ Neutral neutral · not a buy · 🎯$18

Price at call : $14.29 — gap to target +26%

Today : $17.25 — gap to target +4%

🎯 on VTRS : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)

in progress (365j)
matures : Mar 2, 22

Raymond James ↗

Feb 23, 21

▲ Outperform · 🎯$19

Price at call : $15.22 — upside +25%

Today : $17.25 — upside +10%

Expected +25% · Actual -6% · Reason (≥ +15%) : ✗ No

🎯 on VTRS : 0% (2 calls matureds) · 📊 on Health : 46.4% · +1.6% (403 calls)

-5.9%

stock -6% · XLV +11%

matured Feb 23, 22

Raymond James ↗

Jan 25, 21

▲ Outperform · 🎯$23

Price at call : $17.23 — upside +33%

Today : $17.25 — upside +33%

Expected +33% · Actual -15% · Reason (≥ +15%) : ✗ No

🎯 on VTRS : 0% (2 calls matureds) · 📊 on Health : 46.4% · +1.6% (403 calls)

-14.8%

stock -15% · XLV +8%

matured Jan 25, 22

Argus Research ↗

Jan 5, 21

■ Hold neutral · not a buy

🎯 on VTRS : no call matured yet · 📊 on Health : 55.3% · +2.1% (159 calls)

in progress (365j)
matures : Jan 5, 22

Frequently asked questions

Should I buy Viatris stock?

This isn't buy advice. For Viatris, the analyst consensus is "Buy", with an average price target of $20.00 (+16% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 50% of the time (2 calls tracked on Viatris). We show the numbers — you decide.

Is it too late to buy Viatris? How high can it go?

The most bullish analyst target on Viatris is $26.00 (+51% above today's price); the average is $20.00. That's the upside they see. Check how reliable those analysts have actually been on Viatris on our site before trusting it.

Is Viatris still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 4 analysts have a real record on Viatris, the best hitting 50% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

Should you invest in Viatris? The case for and against

The arguments for and against, one by one, from the numbers: why invest in VTRS (and why hesitate).

What has Viatris's past performance been?

Historical returns and a "how much if I had invested" calculator: VTRS performance & returns.

Does Viatris pay a dividend?

Yield, consistency and growth history of the dividend: VTRS's dividend.